Company Overview

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

We have pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of functional GI disorders and inflammatory bowel disease. We discovered, are developing and retain 100% worldwide rights to our proprietary uroguanylin analog technology platform that includes two lead product candidates - plecanatide and dolcanatide.

Plecanatide is our first uroguanylin analog currently being evaluated for use as a once-daily tablet for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally similar to the body's naturally occurring GI peptide, uroguanylin, with the exception of a single amino acid change. Plecanatide is designed to replicate the activity of uroguanylin by working locally in the upper GI tract to stimulate digestive fluid movement and support regular bowel function. In 2015, we announced positive phase 3 data with plecanatide in two pivotal CIC clinical trials. The plecanatide new drug application (NDA) in CIC is currently under review by the Food and Drug Administration (FDA) and the FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017. Additionally, we are evaluating plecanatide in two phase 3 IBS-C trials and we expect top-line data from both pivotal trials in the fourth quarter of this year. We intend to file our second plecanatide NDA in IBS-C in the first quarter of 2017. Beyond these two indications, we are also evaluating opioid-induced constipation (OIC) as a potential life-cycle growth opportunity for plecanatide.

Dolcanatide is our second uroguanylin analog currently being explored for ulcerative colitis. Dolcanatide is designed to replicate the activity of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine. In January 2016, we announced positive proof-of-concept with dolcanatide in a phase 1b trial evaluating 28 patients with mild-to-moderate ulcerative colitis. We are planning to meet with regulatory agencies to discuss phase 2 clinical development plans for dolcanatide in mild-to-moderate ulcerative colitis. In November 2014, we reported successful proof-of-concept with dolcanatide in a double-blind, placebo-controlled phase 2 trial in 289 patients with OIC, demonstrating the utility of our uroguanylin analog technology platform in OIC.

ContraVir Stock Distribution—Information Statement

Stock Information

SGYP

NASDAQ

Volume

Market Cap

Change

DayHigh

Day Low

Events

Upcoming Event

American College of Gastroenterology (ACG) Annual Scientific Meeting

Oct 17, 2016 • 10:30AM - 4:00PM PDT

Archived Event

OktoberINVESTfest 5th Annual Investors Conference

Sep 28, 2016 • 11:30AM EDT

Webcast

Archived Event

Rodman & Renshaw 18th Annual Global Investment Conference

Sep 12, 2016 • 5:30PM EDT

Webcast

View All Events